Sapropterin (Dr. Reddy's – April)

May 2024Pharmacy Updates

Dr. Reddy's Laboratories Ltd. has recalled six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg. Sapropterin is used to reduce blood levels of a certain amino acid in people with a rare, inherited disorder called phenylketonuria.

This drug is being recalled because discolored powder was found in it during laboratory testing. It may decrease the effectiveness of the product.

As of April 23, 2024, there had been no reports of adverse events related to this recall.

To learn if your medication was recalled, contact your doctor or the pharmacy where you received the medication, or visit the FDA website below.

Consumers who have Sapropterin Dihydrochloride Powder for Oral Solution 100 mg from a recalled lot should contact their doctor about next steps before stopping use of the product. Recalled medicine should be returned to the place of purchase.

To learn more about this recall, you can take one or more of the steps below.

  • Talk to your doctor or pharmacist.
  • Call Dr. Reddy's Laboratories at 1-866-733-3952. TTY users should call 711. Help is available Monday through Friday from 9 a.m. to 5 p.m. EST.
  • Visit the FDA website.

Recent Announcements

Important announcement – Telehealth submissions

As of October 1, 2025, UPMC Health Plan continues to accept the submission of telehealth claims. Providers may conduct telehealth visits for UPMC Health Plan members in all UPMC Insurance products. UPMC Insurance products include UPMC Advantage group and individual products, UPMC for Life Medicare Advantage plans, UPMC for Kids CHIP plans, UPMC Community HealthChoices, and UPMC for You Medical Assistance plans.
Sep. 2025Important Notices

October 2025 UPMC for You and UPMC Community HealthChoices Formulary Update

Effective October 1st, 2025, Xifaxan and Retin-A (cream, gel) will no longer be covered by UPMC for You and UPMC Community HealthChoices due to non-participation in the Medicaid Drug Rebate Program.
Sep. 2025Pharmacy Updates

Biosimilar Medication Formulary Updates

Updates to formulary biosimilar medications for denosumab, eculizumab, and ustekinumab products
Sep. 2025Pharmacy Updates